Metagenomi Therapeutics (MGX) EBT Margin (2023 - 2026)
Metagenomi Therapeutics' (MGX) quarterly EBT Margin came in at 1846.88% in Q1 2026, down 124254.0% year-over-year from N/an in Q1 2025, and down 221.11% quarter-over-quarter from 575.15% in Q4 2025.
Powered by 
Analysis
Metagenomi Therapeutics (MGX) EBT Margin (2023 - 2026) Analysis & Trends
Metagenomi Therapeutics (MGX) has reported EBT Margin for 4 consecutive years, with 1846.88% the latest figure, recorded in Q1 2026.
- On a quarterly basis, EBT Margin fell 124254.0% year-over-year to 1846.88% in Q1 2026; TTM through Mar 2026 was 385.27%, a 20109.0% decrease from a year earlier, with the FY2025 full-year figure at 348.77%, down 18897.0% from the prior year.
- EBT Margin was 1846.88% for Q1 2026 at Metagenomi Therapeutics, down from 575.15% in the prior quarter.
- Over five years, EBT Margin peaked at 64.66% in Q2 2024 and troughed at 1846.88% in Q1 2026.
- A 4-year average of 366.8% and a median of 225.36% in 2024 frame the typical range for EBT Margin.
- Across the five-year window, EBT Margin jumped 3333 bps in 2024 and slumped 124254 bps in 2026, its largest moves.
- Over 4 years, EBT Margin stood at 133.62% in 2023, then slumped by 92 bps to 255.94% in 2024, then sank by 125 bps to 575.15% in 2025, then sank by 221 bps to 1846.88% in 2026.
- The last three EBT Margin figures came in at 1846.88% (Q1 2026), 575.15% (Q4 2025), and 238.21% (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.60 Bn | 9.76 Bn | 112.79 Mn | 55.43% |
| 2 | CRISPR Therapeutics AG | 5.39 Bn | 5.39 Bn | - | -885.91% |
| 3 | Iovance Biotherapeutics | 3.98 Bn | 3.68 Bn | 55.72 Mn | -49.02% |
| 4 | Legend Biotech | 3.97 Bn | 3.00 Bn | 251.50 Mn | 14.32% |
| 5 | uniQure | 3.09 Bn | 3.09 Bn | 5.49 Mn | -1,356.24% |
| 6 | Beam Therapeutics | 3.06 Bn | 3.06 Bn | - | -24,299.18% |
| 7 | Precigen | 2.54 Bn | 2.54 Bn | 52.17 Mn | 36.51% |
| 8 | Sarepta Therapeutics | 2.38 Bn | 1.58 Bn | 251.87 Mn | -0.44% |
| 9 | Vericel | 2.06 Bn | 1.89 Bn | 56.40 Mn | 2.88% |
| 10 | Metagenomi Therapeutics | 44.20 Mn | 44.20 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -1,846.88% |
| Dec 31, 2025 | -575.15% |
| Sep 30, 2025 | -238.21% |
| Jun 30, 2025 | -233.34% |
| Mar 31, 2025 | -604.34% |
| Dec 31, 2024 | -255.94% |
| Sep 30, 2024 | -181.34% |
| Jun 30, 2024 | -64.66% |
| Mar 31, 2024 | -225.36% |
| Dec 31, 2023 | -133.62% |
| Sep 30, 2023 | -150.56% |
| Jun 30, 2023 | -98.00% |
| Mar 31, 2023 | -160.98% |